Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colchicine + cyclophosphamide is a combination of two small molecule drugs, each with distinct mechanisms of action. Colchicine is an anti-inflammatory agent that inhibits microtubule polymerization by binding to tubulin, thereby disrupting cellular processes such as mitosis and neutrophil activity. Cyclophosphamide is an alkylating agent that suppresses the immune system by cross-linking DNA strands, leading to cell death, particularly in rapidly dividing cells. This combination has been explored for use in autoimmune and inflammatory diseases such as Behçet's disease and idiopathic pulmonary fibrosis (IPF), though evidence for efficacy is limited[1][2]. Both agents are well-established pharmaceuticals with broad clinical histories.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colchicine + cyclophosphamide.